

DOAC-Remove™

For the removal of DOACs from plasma specimens

DOAC-Remove™ tablets are intended to be used for removal of Direct Oral Anticoagulants (DOACs) compounds from human citrated plasma samples, including dabigatran, rivaroxaban, apixaban and edoxaban. It also successfully removes the direct thrombin inhibitor argatroban from plasma samples.

DOAC-Remove™ reduces the false positivity for lupus anticoagulants tests on DOAC-containing plasmas and is useful for eliminating interference of DOACs on routine coagulation assays such as APTT, PT, TT, single factors and APC-R in research settings.



Procedure



Step 1

Add one DOAC-Remove™ tablet to about 1 mL (range 0.5 to 2 mL) of citrated plasma

Step 2

Gently mix the sample for 10 minutes

Step 3

Centrifuge for 2 minutes at 5000g

The plasma supernatant is now free of DOACs and can be used for immediate coagulation testing or can be frozen in aliquots for future applications

Product overview

Article No.	Product name	Quantity
A5D-82410A-RUO	DOAC-Remove™	20 tablets
A5D-82410B-RUO	DOAC-Remove™	50 tablets
A5D-82410C-RUO	DOAC-Remove™	250 tablets

Contact Aniara Diagnostica, Inc. :

Aniara Diagnostica, Inc.
7768 Service Center Dr. West Chester,
OH, 45069, United States

Tel: +1 513-770-1991
Email: info@aniara.com
Website: www.aniara.com